韩国皮肤型红斑狼疮发病率及系统性进展全国研究
该研究利用韩国国民健康保险数据库(2005-2020)识别32,337例皮肤型红斑狼疮(CLE)患者,分析其发病率、皮肤癌风险及进展为系统性红斑狼疮(SLE)的风险。结果显示CLE年均发病率为3.98/10万人年,与癌前病变和皮肤恶性肿瘤风险升高相关,5年进展为SLE的累积发生率为11.4%。
要点
- CLE年均发病率为3.98/10万人年(95%CI 3.94-4.03),呈小幅上升趋势(p=0.014)。
- CLE与光化性角化病及皮肤恶性肿瘤风险升高相关,前2年最显著但随访期持续存在。
- CLE进展为SLE的5年累积发生率为11.4%,亚急性皮肤型(20.8%)高于盘状(9.5%)。
核心结论
- 韩国CLE发病率与既往基于人群的估计相当,且CLE与癌前及恶性皮肤病变风险升高相关。
- CLE进展为SLE多集中在诊断后5年内,建议在此期间进行风险分层评估。
研究设计与样本
- 基于韩国国民健康保险服务-国家健康信息数据库(2005-2020)的全国性人群研究。
- 共识别32,337例CLE患者,平均(SD)年龄42.9(17.4)岁,女性23,436例(72.5%)。
- 采用时间-事件分析和累积发病率估计评估进展至SLE的风险。
主要发现
- 5,367例(16.6%)合并SLE;盘状红斑狼疮最常见(22,463例,69.5%),其次为其他局限性LE(8,594例,26.6%)和亚急性皮肤型红斑狼疮(3,465例,10.7%)。
- 年均CLE发病率为3.98/10万人年(95%CI 3.94-4.03),呈小幅上升趋势(p=0.014)。
- 563例(2.0%)在CLE诊断后进展为SLE,平均(SD)进展时间3.2(3.0)年。
- 5年进展为SLE的累积发生率为11.4%,亚急性皮肤型红斑狼疮高于盘状红斑狼疮(20.8% vs. 9.5%)。
- CLE与光化性角化病及皮肤恶性肿瘤风险升高相关,前2年最显著但随访期持续存在。
临床怎么用
- 临床应告知CLE患者皮肤癌风险升高,并建议定期皮肤检查。
- 对CLE患者,尤其亚急性皮肤型红斑狼疮,应在诊断后5年内进行风险分层随访以监测SLE进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous lupus erythematosus (CLE) is an LE-specific cutaneous manifestation that can occur in isolation or with systemic lupus erythematosus (SLE). Estimates of CLE incidence, skin cancer burden and progression to SLE in Asian populations are limited. OBJECTIVES: To investigate the nationwide incidence of CLE in Korea, its association with premalignant and malignant skin lesions and the risk of progression to SLE. METHODS: This population-based study used the Korean National Health Insurance Service-National Health Information Database (2005-2020). CLE was identified using ICD-10 code L93; cases with SLE were included, whereas cases without SLE required ancillary testing or prescriptions. CLE and SLE diagnoses within 6 months were considered concurrent. Progression to SLE was assessed using time-to-event analyses and cumulative incidence estimates. RESULTS: Overall, 32,337 patients with CLE were identified [mean (SD) age, 42.9 (17.4) years; 23,436 (72.5%) female], and 5367 (16.6%) had concomitant SLE. Discoid lupus erythematosus (DLE) was the most common subtype (22,463 [69.5%]), followed by other localized LE (8594 [26.6%]) and subacute cutaneous lupus erythematosus (SCLE) (3465 [10.7%]). Mean annual CLE incidence was 3.98 per 100,000 person-years (95% CI, 3.94-4.03), with a modest upward trend (p for trend = 0.014). CLE was associated with higher risks of actinic keratosis and cutaneous malignancies, most pronounced within the first 2 years but remaining significant during follow-up. A total of 563 patients (2.0%) developed SLE after CLE diagnosis, and the mean (SD) time to progression was 3.2 (3.0) years. Overall 5-year cumulative incidence of progression to SLE was 11.4%, higher in SCLE than DLE (20.8% vs. 9.5%). CONCLUSIONS: CLE incidence in Korea was comparable to prior population-based estimates, and CLE was associated with a higher risk of premalignant and malignant skin lesions. Considering progression from CLE to SLE clustered within the first 5 years after CLE diagnosis, risk-stratified evaluation during this period may be warranted. Cutaneous lupus erythematosus (CLE) is a form of lupus that mainly affects the skin. Some people have only skin symptoms, whereas others may also develop systemic lupus erythematosus (SLE), which can affect internal organs. Information on how often CLE occurs and how often it progresses to SLE has been limited in Asian populations. Using the South Korean National Health Insurance database (2005–2020), we identified 32,337 patients with CLE and examined how often CLE occurred, the risk of skin cancer and the risk of progression to SLE over time. We found that the average annual incidence of CLE in Korea was 3.98 cases per 100,000 people, which is similar to rates reported in previous studies. Patients with CLE had a higher risk of actinic keratosis (precancerous skin lesions) and skin cancer. Progression from CLE to SLE was uncommon overall, and the risk of progression differed by CLE subtype. The average time to SLE diagnosis was 3.2 years, and the 5‐year cumulative incidence of progression to SLE was 11.4%, indicating that most progression occurred within the first 5 years after CLE diagnosis. These findings provide nationwide data on CLE in Korea and may help clinicians counsel patients about skin cancer risks and the likelihood of progression to SLE, supporting personalized follow‐up plans based on each patient's risk.
引用
- Song SY, Kim J, Kim YM, et al. Incidence of cutaneous lupus erythematosus and systemic progression: A Nationwide study in Korea. J Eur Acad Dermatol Venereol. 2026. PMID: 42307259. doi:10.1111/jdv.70555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。